MedTrace Logo

Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study

NCT02548455 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 499

Last updated 2019-02-04

Study results available
· View outcomes & findings →

Summary

The primary intent of this study is to assess the safety of the model 1457Q Quartet LV lead at 3 months in a patient population indicated for cardiac resynchronization therapy.

Conditions

Interventions

DEVICE

Quartet 1457Q LV Lead

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • David Delurgio, MD · Emory University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-27
Primary Completion
2016-08-19
Completion
2017-03-21
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02548455 on ClinicalTrials.gov